Shang Hai Zheng Quan Bao·2025-10-10 18:29Core Viewpoint - The controlling shareholder and chairman of Shanghai Junshi Biosciences Co., Ltd., Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB 100 million over the next 12 months, with a minimum of RMB 50 million allocated for A-shares [2]. Group 1: Shareholding Increase Plan - Mr. Xiong intends to start the share purchase from April 12, 2025, using methods permitted by the Shanghai Stock Exchange and Hong Kong Stock Exchange, including but not limited to centralized bidding and block trading [2]. - As of October 11, 2025, the share purchase plan is more than halfway through, but Mr. Xiong has not yet made any purchases due to factors such as reporting windows, equity incentive matters, and funding arrangements [5]. - The plan remains unfulfilled, and Mr. Xiong will continue to seek opportunities to increase his shareholding during the implementation period [5]. Group 2: Shareholding Details - Mr. Xiong directly holds 87,856,618 shares in the company, which includes 87,854,018 A-shares and 2,600 H-shares, with the latter held by HKSCC NOMINEES LIMITED as a nominal holder [3]. - The shareholding percentage is calculated based on the company's total share capital of 1,026,689,871 shares [3][4]. Group 3: Risk Factors - The share purchase plan may face risks due to changes in capital market conditions or other unpredictable factors that could prevent the plan from achieving its intended outcomes [6][8]. - The implementation of the share purchase plan will not lead to changes in the company's controlling shareholder or actual controller [7].